Exelixis, Inc. $EXEL Shares Acquired by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. increased its stake in Exelixis, Inc. (NASDAQ:EXEL) by 99.3% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,111,933 shares of the biotechnology company’s stock after purchasing an additional 1,052,008 shares during the quarter. Exelixis accounts for 0.7% of Jupiter Asset Management Ltd.’s investment portfolio, making the stock its 29th largest position. Jupiter Asset Management Ltd.’s holdings in Exelixis were worth $87,223,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Richardson Financial Services Inc. lifted its position in shares of Exelixis by 95.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 292 shares during the period. Root Financial Partners LLC purchased a new stake in Exelixis during the third quarter worth $28,000. Luminist Capital LLC grew its holdings in Exelixis by 2,740.0% during the 2nd quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 685 shares during the last quarter. Abich Financial Wealth Management LLC purchased a new position in Exelixis during the third quarter worth $47,000. Finally, Hantz Financial Services Inc. raised its holdings in shares of Exelixis by 940.4% in the second quarter. Hantz Financial Services Inc. now owns 1,134 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 1,025 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Stock Down 0.7%

NASDAQ:EXEL opened at $44.16 on Friday. The company has a market cap of $11.47 billion, a P/E ratio of 15.94, a P/E/G ratio of 1.00 and a beta of 0.42. Exelixis, Inc. has a fifty-two week low of $32.38 and a fifty-two week high of $49.62. The firm’s 50 day moving average is $43.83 and its two-hundred day moving average is $41.15.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.20. The company had revenue of $598.66 million during the quarter, compared to analysts’ expectations of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The business’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.55 EPS. Research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

EXEL has been the topic of a number of analyst reports. Royal Bank Of Canada lifted their price objective on Exelixis from $45.00 to $46.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 11th. Wolfe Research assumed coverage on shares of Exelixis in a research note on Tuesday, November 18th. They set a “peer perform” rating on the stock. Guggenheim downgraded shares of Exelixis from a “buy” rating to a “neutral” rating in a report on Monday, November 3rd. HC Wainwright upped their price objective on shares of Exelixis from $52.00 to $54.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Finally, UBS Group set a $41.00 target price on shares of Exelixis in a research report on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Exelixis currently has a consensus rating of “Hold” and an average price target of $47.11.

Insider Activity

In other news, Director Bob Oliver sold 30,250 shares of the business’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $43.81, for a total transaction of $1,325,252.50. Following the completion of the sale, the director owned 21,120 shares in the company, valued at approximately $925,267.20. The trade was a 58.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christopher J. Senner sold 30,617 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $43.67, for a total transaction of $1,337,044.39. Following the sale, the chief financial officer directly owned 976,092 shares of the company’s stock, valued at approximately $42,625,937.64. This trade represents a 3.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 185,484 shares of company stock valued at $8,077,993 in the last 90 days. 2.82% of the stock is owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.